Ezalife announced clinical results showing its Button Huggie device achieved a 77% reduction in feeding tube dislodgement, addressing what the company describes as a long-standing challenge in patient care. The findings come as the company positions itself in the $1.9 billion feeding tube market, which has seen little innovation in securing methods for decades.
Traditional feeding tube securement typically involves tape and gauze, approaches that Ezalife notes often lead to patient discomfort, complications, and emergency interventions. The Button Huggie is a purpose-built, FDA-registered device designed to stabilize G-tubes more effectively. Beyond the clinical metric, the company reported a 270% increase in parent satisfaction compared to traditional methods and a Net Promoter Score of 76, which it states is significantly higher than the industry average of 46.
The company emphasized that the results highlight both clinical effectiveness and impact on daily life for patients and caregivers. The device is protected by a granted U.S. patent with 18 claims and has additional international patents across Europe, the UK, Canada, China, and Japan. This intellectual property portfolio reinforces Ezalife's position as an innovator in a critical yet underserved segment of post-operative and long-term care.
The announcement coincides with the approaching close of the company's StartEngine campaign on April 6, 2026, which has drawn investor attention to the intersection of healthcare innovation and clinical validation. Ezalife develops precision-engineered medical devices aimed at improving safety and quality of life for patients requiring feeding tubes, with a mission to replace outdated standards of care.
